Our organization successfully designed a platform that enabled all patients - regardless of geography, previous advocacy experience, or disease limitations – to participate in research discussions. The regulatory issue was eliminated by having our organization serve as a communication "bridge" between the patient community and industry representatives. Participants were contacted post-research to help us understand what worked, and what needed improvement, as the Hub is built out for use in the next phase. For example, we tested different research group sizes, provided options to submit answers post-session, and grouped participants on teams.
Patient leaders. By using research professionals as advisors, with our organization and other patient advocates in lead roles, focus group engagement and retention was high and the potential for cost savings was realized. The quality of the data was robust, as patient moderators were able to successfully probe conversations to deeper levels. Additionally, adding a patient to the qualitative analysis team proved beneficial, as key themes were identified that were not realized using software and review by non-patients.
Using a patient as a focus group moderator was also tested at OMERACT (Outcome Measures in Rheumatology) 2018 by our organization's CEO - and ACT Project Manager/Patient Researcher Liaison. The quality of the data was so robust that the methodology was highlighted at the close of the meeting as a new approach to research that should be replicated.
Research.
It was clear in the analysis reatment decision drivers were highly driven by the duration of disease, delay in diagnosis/treatment, dual diagnosis/co-morbidities and access to treatments (healthcare systems), there is a need to explore patient subgroups, particularly those who present ‘atypical’ (“Typical Atypical” subgroups).
ACT Live!
As a result of ACT Live, we realized that as more people join existing stakeholder groups, and experience advances, levels of expertise are developing. This, in turn, is creating ‘subgroups’ within the original groups (i.e. Patient/Novice, Patient/Sophomore, Patient/Advocate, Patient/Advanced, Patient/Expert, Patient/Professional Researcher ), which will inevitably influence project design and patient selection. Additionally, we noted not all those participating in the space, regardless of stakeholder group, were using the same terminology, nor were they all aware of important projects and/or publications completed by those outside of their own affiliation; as more people enter the space this could cause confusion, failure to longitudinally measure the value of patient-research collaboration, and a duplication of efforts.
Roundtable
As a result of the Roundtable, our organization was able to draft a timeline of patient-engagement in rheumatology research (1998 - 2017), begin to track current methods and terminology currently in use, and establish preliminary recommendations for determining when to establish a ‘new method’ or expand on an existing one.
During the session, it was realized that even among the most active in patient-research collaboration projects, universal verbiage and project sharing is lacking. Not only could this cause confusion as new parties enter the collaboration space, but it can negatively affect efforts to collectively measure the value of incorporating patients in the research process. Failure to track important initiatives can lead to a duplication of efforts, resulting in wasted time and research dollars.
Guidance and reference materials will become particularly important as “patient-centered” efforts continue to popularize as new parties enter the space. Attendees agreed there is a need to form an alliance of individuals to preserve the history of patient engagement and to track the evolution of terminology and methodology so efforts are not duplicated, the value of engagement can be measured, and barriers and benefits of new stakeholder subgroups (i.e. patient levels) can be identified and used to advance innovation. These individuals should include one expert representatives from each major stakeholder group and/or organization pivotal in advancing patient engagement in research, and led predominately by the patients who have paved the way for future generations of patient voices.